The European Patent Office has issued a patent covering the Akers Biosciences’ Breath Ketone Detector, a single-use, non-invasive, breath device to rapidly monitor ketone levels.
The Patent, which was granted U.S. patent protection in 2014, protects both the methods and devices related to the Breath Ketone Detector. The Breath Ketone Detector was developed utilizing Akers Bio’s proprietary MPC Biosensor Technology platform which facilitates the rapid identification of medical or metabolic conditions through biomarkers in exhaled breath condensate.
Ketones are acids which have the potential to build up in the body causing a condition referred to as ketosis. An extreme form of this condition is a life-threatening medical emergency called ketoacidosis. At-risk populations for this severe form of ketosis include those with diabetes, and people who subscribe to restrictive ketogenic diets for epilepsy management or to obtain aggressive weight loss results.
The company’s Breath Ketone Detector detects the presence of ketones in a person’s breath condensate.
“Having robust protection over our intellectual property is of paramount importance for safeguarding the value of our inventions. We are delighted to have been awarded this Patent which offers broad coverage and has been some years in the making,” said Raymond F. Akers, Jr., Ph.D., Co-founder and Chief Scientific Director.
“Achieving patent protection in the key territories of the U.S. and Europe is very significant for the Breath Ketone Detector technology because of the enormous target markets of diabetes and health and wellness that we are positioning the tests for,” continued Dr. Akers.